Dr. Vokes on Biomarker Selection in Head and Neck Cancer

Everett Vokes, MD
Published: Wednesday, Mar 22, 2017



Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.

PD-L1 is an imperfect selection factor, says Vokes, but it can enrich in patients who are likely to respond to immunotherapy. There is no clear cutoff between patients who will and patients who will not respond, though, calling for a more selective biomarker.
 


Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.

PD-L1 is an imperfect selection factor, says Vokes, but it can enrich in patients who are likely to respond to immunotherapy. There is no clear cutoff between patients who will and patients who will not respond, though, calling for a more selective biomarker.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder CancersAug 31, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x